Jaehyuk Choi

Jaehyuk Choi

Auto-generated profile, based on publicly available information

Jaehyuk Choi

Hanmi Research Center, Hanmi Pharm. Co. Ltd., Gyeonggi-do, Republic of Korea (J.C., J.L., E.P., H.K., D.K., S.B., IY.C.); Biotherapeutics and Glycomics Laboratory, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea (J.C., HH.K.); and Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea (HH.K.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JCJae-Hyuk Choi
Jae-Hyuk Choi
Sung Yong OhSung Yong Oh
Sung Yong Oh
HKHyuk-Chan Kwon
Hyuk-Chan Kwon
JKJung-Hwan Kim
Jung-Hwan Kim
Jae Hoon LeeJae Hoon Lee
Jae Hoon Lee
HKHyo-Jin Kim
Hyo-Jin Kim
Choi JH, et al. Cancer Res Treat. 2008 Mar;40(1):22-26. http://dx.doi.org/10.4143/crt.2008.40.1.22

21 November 2022 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
JCJaehyuk Choi
Jaehyuk Choi
JLJinbong Lee
Jinbong Lee
EPEunjin Park
Eunjin Park
HKHyunjoo Kwon
Hyunjoo Kwon
DKDaejin Kim
Daejin Kim
HKHa Hyung Kim
Ha Hyung Kim
Extensive bowel resection caused by various diseases that affect the intestines, such as Crohn9s disease, volvulus, and cancer, leads to short bowel syndrome (SBS). Teduglutide is the only approved glucagon-like peptide-2 (GLP-2) drug for SBS; however, it requires daily administration. A novel GLP-2 analog with a prolonged duration of action to reduce dosing frequency and promote a greater efficacy may provide patients with a better quality of life. In the present study, the sustained exposure of HM15912 was characterized in normal male rats. The efficacy of HM15912 on intestinal growth and absorption capacity was also evaluated in normal male mice, rats, and SBS rats. HM15912 exhibited a remarkably extended half-life (42.3 h) compared to teduglutide (0.6 h) in rats. Despite of somewhat lower in vitro potency on GLP-2 receptor than human GLP-2 or teduglutide, this longer-lasting mode of action promotes HM15912 to be more effective in terms of small intestinal growth than existing GLP-2 analogs even with a less frequent dosing interval of as little as once a week in rodents including SBS rats. Furthermore, the small intestinal weight was approximately doubled, and the D-xylose absorption was significantly increased after pre-treatment of existing GLP-2 analogs on the market or under clinical development followed by HM15912 in rodents. These results indicate that HM15912 possesses a significant small bowel trophic effect driven by continuously increased exposure, supporting that HM15912 may be a novel treatment option with greater efficacy and the longest dosing interval among existing GLP-2 analogs for SBS with intestinal failure. Significance Statement HM15912, a novel long-acting GLP-2 analog, has a significant small bowel hypertrophic effect in rodents with a reduced frequency of administration compared to the existing GLP-2 analogs on the market or currently under clinical development. This study supports the possibility that HM15912 could be administered much less frequently than other long-acting GLP-2 analogs for patients with SBS.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
JLJong Suk Lee
Jong Suk Lee
SLSeon Myeong Lee
Seon Myeong Lee
JCJaehyuk Choi
Jaehyuk Choi
EPEunjin Park
Eunjin Park
JLJongsoo Lee
Jongsoo Lee
ICIn Young Choi
In Young Choi
Obesity is a major risk factor for a number of metabolic disorders such as hyperlipidemia, glucose intolerance, and T2DM. Recent researches indicated a stimulatory effect of glucagon (GCG) on energy expenditure and appetite inhibition, suggesting the utilization of GCG as a pharmacological therapy for obesity and related metabolic disorders. In line with this, we previously observed that chronic treatment of HM15136, a novel long-acting glucagon analog, conferred efficient body weight loss (BWL) in DIO mice. Here, we further investigated the potential benefits of HM15136 in obesity-related metabolic disorders. In DIO mice, time-course change in fat mass, liver triglyceride (TG), and fasting blood glucose (FBG) was determined. Chronic treatment of HM15136 was associated with progressive BWL (-37.5% vs. vehicle (Veh) at day17) and fat mass reduction with little effect on lean mass, confirming its potent anti-obesity effect. Interestingly, despite marginal BWL at initial drug treatment period, significant reduction in blood TG (-56.5% vs. Veh at day2) and subsequent liver TG (-41.5% vs. Veh at day7) was achieved, and maintained thereafter. Moreover, the TG lowering both in blood and liver was followed by sustainable FBG lowering, suggesting that rapid depletion of lipid, the main sources for gluconeogenesis, might contribute to FBG control by HM15136. To evaluate the potential effect on post-prandial glucose control, oral glucose tolerance test (oGTT) was performed, and reduced BG level during oGTT was observed as BWL occurred. Time-dependent reduction in HOMA-IR evidenced the insulin sensitivity improvement. To our knowledge, this is the first study demonstrating the potential benefits of chronic GCG engagement in the management of BW, blood lipid, and even BG. Based on these results, HM15136 may be a novel option for the management of obesity and related metabolic disorders. Human study is ongoing for the clinical relevance of these findings. Disclosure J. Lee: Employee; Self; Hanmi Pharmaceutical. S. Lee: Employee; Self; Hanmi Pharmaceutical. J. Choi: Employee; Self; Hanmi Pharmaceutical. E. Park: Employee; Self; Hanmi Pharmaceutical. J. Lee: Employee; Self; Hanmi Pharmaceutical. S. Lee: Employee; Spouse/Partner; Hanmi Pharmaceutical. S. Bae: Employee; Self; Hanmi Pharmaceutical. D. Kim: Board Member; Self; Hanmi Pharmaceutical. I. Choi: Board Member; Self; Hanmi Pharmaceutical.